BR112014005700A2 - composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico - Google Patents

composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico

Info

Publication number
BR112014005700A2
BR112014005700A2 BR112014005700A BR112014005700A BR112014005700A2 BR 112014005700 A2 BR112014005700 A2 BR 112014005700A2 BR 112014005700 A BR112014005700 A BR 112014005700A BR 112014005700 A BR112014005700 A BR 112014005700A BR 112014005700 A2 BR112014005700 A2 BR 112014005700A2
Authority
BR
Brazil
Prior art keywords
prostaglandin
hyaluronic acid
ophthalmic compositions
alpha derivatives
alpha
Prior art date
Application number
BR112014005700A
Other languages
English (en)
Inventor
Hadj-Slimane Reda
Original Assignee
Visiotact Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visiotact Pharma filed Critical Visiotact Pharma
Publication of BR112014005700A2 publication Critical patent/BR112014005700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico a presente invenção refere-se a uma composição compreendendo pelo menos um análogo de prostaglandina como composto ativo e umuma quantidade estabilizante de pelo menos ou um sal do mesmo, a dita composição sendo livre de conservante; e ao uso da mesma para o uso no tratamento de hipertensão ocular e/ou glaucoma em um indivíduo em necessidade da mesma.
BR112014005700A 2011-09-12 2012-09-11 composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico BR112014005700A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306137A EP2567689A1 (en) 2011-09-12 2011-09-12 Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
PCT/EP2012/003810 WO2013037479A1 (en) 2011-09-12 2012-09-11 Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid

Publications (1)

Publication Number Publication Date
BR112014005700A2 true BR112014005700A2 (pt) 2017-03-28

Family

ID=46875737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005700A BR112014005700A2 (pt) 2011-09-12 2012-09-11 composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico

Country Status (13)

Country Link
US (1) US20140228364A1 (pt)
EP (2) EP2567689A1 (pt)
JP (1) JP2014528930A (pt)
CN (1) CN103957887B (pt)
AU (1) AU2012307812A1 (pt)
BR (1) BR112014005700A2 (pt)
CA (1) CA2848156A1 (pt)
ES (1) ES2792061T3 (pt)
IL (1) IL231264A0 (pt)
MX (1) MX2014002918A (pt)
PL (1) PL2763654T3 (pt)
WO (1) WO2013037479A1 (pt)
ZA (1) ZA201401787B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
US9115109B2 (en) * 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
WO2016013993A1 (en) * 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
MX2017004809A (es) 2014-10-15 2017-07-26 Novartis Ag Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
ES2776370T3 (es) * 2015-01-27 2020-07-30 Apharm Srl Combinación de ácido hialurónico y macrogol, y composiciones farmacéuticas que la contienen
RU2576778C1 (ru) * 2015-02-20 2016-03-10 Илья Александрович Марков Фармацевтическая композиция в виде гелеобразных глазных капель для лечения глаукомы
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
GR1009006B (el) * 2016-04-01 2017-04-04 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
EA202092471A1 (ru) * 2018-04-18 2021-03-25 Ай.КОМ МЕДИКАЛ ГМБХ Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела
CN109172580B (zh) * 2018-09-06 2021-04-27 中山万汉制药有限公司 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂
CN110711175A (zh) * 2019-11-12 2020-01-21 南京华盖制药有限公司 一种他氟前列素滴眼剂及其制备方法
WO2021158589A1 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors
KR20230041692A (ko) * 2020-06-21 2023-03-24 이콤 메디칼 게엠베하 고안압증 및 녹내장의 치료 및 예방을 위한 히알루론산계 제제
JP6855026B1 (ja) * 2020-11-09 2021-04-07 東亜薬品株式会社 タフルプロスト点眼液
CN114295741A (zh) * 2021-12-17 2022-04-08 沈阳兴齐眼药股份有限公司 对包含在溶液样品中的曲伏前列素和曲伏前列素酸同时进行定量分析的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
KR100489759B1 (ko) 1996-12-09 2005-05-16 바슈 앤드 롬 인코포레이티드 일회용 가요성 컨테이너
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EP1011728B1 (en) 1998-07-14 2004-12-29 Alcon Manufacturing, Ltd. Polypropylene containers for prostaglandin products
ES2357551T3 (es) 2000-09-13 2011-04-27 Santen Pharmaceutical Co., Ltd. Colirio.
CN1488404A (zh) * 2003-06-19 2004-04-14 刘继东 眼用制剂中玻璃酸钠的复合应用
EP1642584A1 (en) * 2003-06-25 2006-04-05 Cardiovascular Institute, Ltd External preparation for improving coital function
ATE450264T1 (de) 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
PL1759702T3 (pl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem
JP2006176457A (ja) * 2004-12-24 2006-07-06 Wakamoto Pharmaceut Co Ltd 医薬用水性液状組成物
US7306129B2 (en) * 2005-11-03 2007-12-11 Stewart Swiss One way valve assembly
CN101282714B (zh) 2005-10-10 2012-12-12 诺瓦加利制药公司 包含前列腺素的眼用乳剂
TW200733993A (en) * 2005-11-03 2007-09-16 Reseal Internat Ltd Partnership Continuously sealing one way valve assembly and fluid delivery system and formulations for use therein
KR100845942B1 (ko) * 2006-07-10 2008-07-11 주식회사태준제약 부작용이 경감된 점안용 조성물과 그의 제조 방법
CA2694929C (en) * 2007-07-26 2016-10-18 Azad Pharma Ag Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

Also Published As

Publication number Publication date
WO2013037479A8 (en) 2014-05-30
US20140228364A1 (en) 2014-08-14
EP2567689A1 (en) 2013-03-13
EP2763654B1 (en) 2020-04-29
MX2014002918A (es) 2014-11-21
CN103957887A (zh) 2014-07-30
CA2848156A1 (en) 2013-03-21
CN103957887B (zh) 2018-02-06
JP2014528930A (ja) 2014-10-30
AU2012307812A1 (en) 2014-04-17
ES2792061T3 (es) 2020-11-06
ZA201401787B (en) 2015-12-23
PL2763654T3 (pl) 2020-11-02
WO2013037479A1 (en) 2013-03-21
IL231264A0 (en) 2014-04-30
AU2012307812A8 (en) 2015-06-11
EP2763654A1 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
BR112014005700A2 (pt) composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
CL2017002650A1 (es) Compuestos novedosos
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
EA201792421A1 (ru) Амидозамещенные производные циклогексана
BRPI0913109B8 (pt) solução aquosa oftálmica
BR112016006926A8 (pt) uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido
CU20130126A7 (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
DOP2014000051A (es) Imidazopiridazinas sustituidas con amino
UY33625A (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
EA201391315A1 (ru) Гуанидиновое соединение
BR112014014378A2 (pt) composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
CR20160433A (es) Nuevos compuestos
BR112014003640A8 (pt) métodos para perda de peso e composições cetogênicas
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BRPI1016257B8 (pt) composições compreendendo finafloxacina para tratamento de infecções óticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]